摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S)-2-(4-piperidin-1-yl-phenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester | 881919-93-3

中文名称
——
中文别名
——
英文名称
(2S)-2-(4-piperidin-1-yl-phenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester
英文别名
ditert-butyl (2S)-2-(4-piperidin-1-ylphenyl)piperazine-1,4-dicarboxylate
(2S)-2-(4-piperidin-1-yl-phenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester化学式
CAS
881919-93-3
化学式
C25H39N3O4
mdl
——
分子量
445.602
InChiKey
MAMXFHXVSBDZKM-OAQYLSRUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    62.3
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS
    申请人:Watanabe Kazutoshi
    公开号:US20090239864A1
    公开(公告)日:2009-09-24
    A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R 1 represents a C 1 -C 12 alkyl; R 2 represents a hydrogen atom or the like; R 3 represents a halogen or the like; q represents an integer of 1 to 7; R 4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R 5 represents a C 6 -C 10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).
    化合物的化学式为(I),其手性异构体,或其药学可接受的盐:其中R1表示C1-C12烷基;R2表示氢原子或类似物;R3表示卤素或类似物;q表示1至7的整数;R4表示卤素或类似物;p表示0或1至5的整数;R5表示C6-C10芳基,杂环或类似物;X表示氧,NH或类似物,用于预防和/或治疗由tau蛋白激酶1高活性引起的疾病,例如神经退行性疾病(如阿尔茨海默病)。
  • 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:US08129377B2
    公开(公告)日:2012-03-06
    A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R1 represents a C1-C12 alkyl; R2 represents a hydrogen atom or the like; R3 represents a halogen or the like; q represents an integer of 1 to 7; R4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R5 represents a C6-C10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).
    化合物的化学式为(I),其手性异构体或药物可接受的盐:其中,R1代表C1-C12烷基;R2代表氢原子或类似物;R3代表卤素或类似物;q代表1至7的整数;R4代表卤素或类似物;p代表0或1至5的整数;R5代表C6-C10芳基,杂环或类似物;X代表氧、NH或类似物,用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病,如神经退行性疾病(例如阿尔茨海默病)。
  • 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP2261224A2
    公开(公告)日:2010-12-15
    A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R1 represents a C1-C12 alkyl; R2 represents a hydrogen atom or the like; R3 represents a halogen or the like; q represents an integer of 1 to 7; R4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R5 represents a C6-C10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).
    由式(I)代表的化合物、其光学活性异构体或其药物可接受盐:其中 R1 代表 C1-C12 烷基;R2 代表氢原子或类似物;R3 代表卤素或类似物;q 代表 1 至 7 的整数;R4 代表卤素或类似物;p 代表 0 或 1 至 5 的整数;R5 代表 C6-C10 芳基、杂环或类似物;X 代表氧、NH 或类似物,用于预防和/或治疗由 tau 蛋白激酶 1 活性亢进引起的疾病,如神经退行性疾病(如阿尔茨海默病)。如阿尔茨海默病)。
  • 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1805164A2
    公开(公告)日:2007-07-11
  • US8129377B2
    申请人:——
    公开号:US8129377B2
    公开(公告)日:2012-03-06
查看更多